Enpatoran

Enpatoran (M5049) is a potent, orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran is inactive against TLR3, TLR4 and TLR9. Enpatoran can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran exhibits excellent pharmacokinetic properties in vivo. Enpatoran can be used for both innate and adaptive autoimmunity blocking research [1].

Product Specifications

CAS Number

[2101938-42-3]

Product Name Alternative

M5049

UNSPSC

12352005

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/enpatoran.html

Purity

99.80

Solubility

DMSO : 24.44 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic)

Smiles

N#CC(C=C1)=C(N=CC=C2)C2=C1N3C[C@@H](C(F)(F)F)C[C@@H](N)C3

Molecular Formula

C16H15F3N4

Molecular Weight

320.31

References & Citations

[1]Jaromir Vlach, et al. Discovery of M5049: A Novel Selective TLR7/8 Inhibitor for Treatment of Autoimmunity. J Pharmacol Exp Ther. 2020 Dec 16; JPET-AR-2020-000275.